



Name	Kota Nakamura
Affiliation	Department of Surgery, Nara Medical University
Country	Japan
Major Field	Surgery

Educational Background

2009 M.D. Nara Medical University

2020 PhD Nara Medical University

Professional Experience

2009: Clinical Resident, Nara Medical University, Japan

2011: Medical Staff in Department of Surgery, Nara Medical University, Japan

2021: Department of Molecular Diagnostics and Experimental Therapeutics,
Beckman Research Institute of City of Hope, U.S.A

2023: Assistant professor in Department of Surgery, Nara Medical University, Japan

Main Scientific Publications

1. **Nakamura K**, Zhu Z, Roy S, et al. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. *Gastroenterology*. 2022;163:1252-1266.e2.

2. **Nakamura K**, Hernández G, Sharma GG, et al. A Liquid Biopsy Signature for the Detection of Patients With Early-Onset Colorectal Cancer. *Gastroenterology*. 2022;163:1242-1251.e2.

3. **Nakamura K**, Nagai M, Matsumoto I, et al. Impact of antithrombotic therapy on postpancreatectomy hemorrhage in 7116 patients: A project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. *J Hepatobiliary Pancreat Sci*. 2023;30:1161-1171.

4. **Nakamura K**, Sho M, Satoi S, et al. Impact of Antithrombotic Agents on Postpancreatectomy Hemorrhage: Results from a Retrospective Multicenter Study. *J Am Coll Surg*. 2020;231:460-469.e1.

5. **Nakamura K**, Sho M, Akahori T, et al. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. *Pancreatology*. 2021;21:573-580.

6. **Nakamura K**, Sho M, Kinoshita S, et al. New insight into the association between bile infection and clinically relevant pancreatic fistula in patients undergoing pancreatoduodenectomy. *J Hepatobiliary Pancreat Sci*. 2020;27:992-1001.

7. **Nakamura K**, Sho M, Akahori T, et al. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer. *World J Surg*. 2019;43:642-648.

8. Nishiwada S, Sho M, **Nakamura K**, et al. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. *Gastroenterology*. 2020;159:562-574.

9. Nishiwada S, **Nakamura K**, Sho M, et al. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma. *Ann Surg*. 2022;276:E876-E885.

10. Akahori T, Sho M, **Nakamura K**, et al. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. *Oncologist*. 2019;24:749-e224.